Nanobiotix マネジメント

マネジメント基準チェック /14

Nanobiotixの CEO はLaurent Levyで、 Mar2003年に任命され、の在任期間は 21.67年です。の年間総報酬は€ 3.40Mで、 12.1%給与と87.9%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の2.4%を直接所有しており、その価値は$ 4.15M 。経営陣と取締役会の平均在任期間はそれぞれ5.3年と2年です。

主要情報

Laurent Levy

最高経営責任者

€3.4m

報酬総額

CEO給与比率	12.1%
CEO在任期間	21.7yrs
CEOの所有権	2.4%
経営陣の平均在職期間	5.3yrs
取締役会の平均在任期間	2yrs

経営陣の近況

Recent updates

Nanobiotix enters final agreement to restructure existing loan with EU's investment bank

Oct 18

Nanobiotix GAAP EPS of -€0.76, revenue of €1.33M beats by €0.11M

Sep 28

Nanobiotix agrees in principle to restructure debt obligations with EU's investment bank

Sep 12

CEO報酬分析

Nanobiotix の収益と比較して、Laurent Levy の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Jun 30 2024	n/a	n/a	-€33m
Mar 31 2024	n/a	n/a	-€37m
Dec 31 2023	€3m	€411k	-€40m
Sep 30 2023	n/a	n/a	-€49m
Jun 30 2023	n/a	n/a	-€59m
Mar 31 2023	n/a	n/a	-€58m
Dec 31 2022	€1m	€380k	-€57m
Sep 30 2022	n/a	n/a	-€50m
Jun 30 2022	n/a	n/a	-€43m
Mar 31 2022	n/a	n/a	-€45m
Dec 31 2021	€4m	€380k	-€47m
Sep 30 2021	n/a	n/a	-€45m
Jun 30 2021	n/a	n/a	-€43m
Mar 31 2021	n/a	n/a	-€39m
Dec 31 2020	€818k	€330k	-€34m
Sep 30 2020	n/a	n/a	-€41m
Jun 30 2020	n/a	n/a	-€48m
Mar 31 2020	n/a	n/a	-€49m
Dec 31 2019	€2m	€330k	-€51m
Sep 30 2019	n/a	n/a	-€46m
Jun 30 2019	n/a	n/a	-€42m
Mar 31 2019	n/a	n/a	-€36m
Dec 31 2018	€1m	€300k	-€30m
Sep 30 2018	n/a	n/a	-€28m
Jun 30 2018	n/a	n/a	-€27m
Mar 31 2018	n/a	n/a	-€26m
Dec 31 2017	€861k	€253k	-€26m

報酬と市場: Laurentの総報酬 ($USD 3.54M ) は、 US市場 ($USD 1.46M ) の同規模の企業の平均を上回っています。

報酬と収益: Laurentの報酬は増加しましたが、会社は利益を上げていません。

CEO（最高経営責任者

Laurent Levy (51 yo)

21.7yrs

在職期間

€3,396,084

報酬

Mr. Laurent Lévy, Ph.D. has been the President of the Executive Board at Nanobiotix S.A. since May 27, 2004 and its Chief Executive Officer since March 2003. Mr. Lévy has a thorough understanding of the te...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Laurent Levy	Co-Founder	21.7yrs	€3.40m	2.4% $ 4.2m
Bart Van Rhijn	Chief Financial & Business Officer and Member of Executive Board	3.4yrs	€1.50m	0% $ 0
Anne-Juliette Hermant	Chief People Officer & Member of Executive Board	5.3yrs	€801.96k	0.30% $ 510.3k
Louis Kayitalire	Chief Medical Officer	1.2yrs	€500.80k	データなし
Earl Bergey	Co-Founder	21.8yrs	データなし	データなし
Craig West	Senior Vice President of Investor Relations	no data	データなし	データなし
Brandon Owens	VP of Strategic Marketing & Corporate Communication	no data	データなし	データなし
Margaret Galluzzi	VP & Global Head of Clinical Operations	5.8yrs	データなし	データなし
Leonard Farber	Chief Clinical and Medical Affairs Officer & Chairman of the Scientific Advisory Board	2.8yrs	データなし	データなし

5.3yrs

平均在職期間

51yo

平均年齢

経験豊富な経営陣: NBTXの経営陣は経験豊富で経験豊富です（平均在職期間は5.3年）。

取締役

名称	ポジション	在職期間	報酬	所有権
Leonard Farber	Chief Clinical and Medical Affairs Officer & Chairman of the Scientific Advisory Board	no data	データなし	データなし
Enno Spillner	Independent Member of Supervisory Board	10.4yrs	€50.00k	データなし
Gary Phillips	Independent Chairman of Supervisory board	3.5yrs	€63.00k	データなし
Silvia Formenti	Member of Scientific Advisory Board	2yrs	データなし	データなし
Alain Herrera	Independent Member of Supervisory Board	11.4yrs	€35.00k	データなし
Anne-Marie Graffin	Independent Vice Chairman of the Supervisory Board	10.9yrs	€42.00k	データなし
Hisham Mehanna	Member of Scientific Advisory Board	2yrs	データなし	データなし
Stephane Champiat	Member of Scientific Advisory Board	2yrs	データなし	データなし
Jean Bourhis	Member of Scientific Advisory Board	2yrs	データなし	データなし
Thierry Baere	Member of Scientific Advisory Board	2yrs	データなし	データなし
Christophe Tourneau	Member of Scientific Advisory Board	2yrs	データなし	データなし
Nancy Lee	Member of Scientific Advisory Board	2yrs	データなし	データなし

2.0yrs

平均在職期間

60.5yo

平均年齢

経験豊富なボード: NBTXの取締役会は経験豊富ではない ( 2年の平均在任期間) ため、新しい取締役会が必要であると考えられます。

Nanobiotix マネジメント

マネジメント 基準チェック /14

主要情報

経営陣の近況

Nanobiotix S.A., Annual General Meeting, Jun 27, 2023

NANOBIOTIX Announces the Appointment of Global Medical Experts to Scientific Advisory Board

Recent updates

Nanobiotix Announces Progress in Global NBTXR3 Development Collaboration Highlighting Robust Pipeline and Pathway to Long-Term Growth

Nanobiotix S.A. to Report Q1, 2024 Results on May 22, 2024

Nanobiotix Announces US FDA Protocol Acceptance for New Randomized Phase 2 Study Evaluating Nbtxr3 for Patients with Stage Three Lung Cancer

Nanobiotix S.A. to Report Q4, 2023 Results on Apr 24, 2024

Nanobiotix S.A. announced that it has received $24.999999 million in funding from Johnson & Johnson Innovation - JJDC, Inc.

Nanobiotix S.A. to Report Q3, 2023 Results on Nov 13, 2023

Nanobiotix S.A. has completed a Follow-on Equity Offering in the amount of $29.288592 million.

Nanobiotix S.A. has filed a Follow-on Equity Offering in the amount of $30 million.

Nanobiotix S.A. announced that it expects to receive $25 million in funding from Johnson & Johnson Innovation - JJDC, Inc.

Nanobiotix S.A. Announces Updated Preliminary Results from Phase 1 Pancreatic Cancer Trial and New Exploratory Analysis from Completed Phase 1 Head and Neck Cancer Trial at ESMO 2023

Nanobiotix S.A. Announces New Clinical Data from Phase 1 Study Evaluating Radiotherapy-Activated Nbtxr3 for Patients with Pancreatic Ductal Adenocarcinoma

Nanobiotix S.A. to Report First Half, 2023 Results on Sep 26, 2023

NANOBIOTIX Announces Expiration of HSR Waiting Period Regarding the Agreement for Worldwide Co-Development and Commercialization of Potential First-in-Class Radioenhancer NBTXR3

Nanobiotix S.A. Announces First Patient Injected in New Phase 1/2 Study Evaluating Radiotherapy-Activated NBTXR3 Plus Anti-PD-1 for Patients With Advanced Cancers

Nanobiotix S.A., Annual General Meeting, Jun 27, 2023

NANOBIOTIX Announces First Patient Randomized in United States in Global Phase 3 Pivotal Trial Evaluating Radioenhancer NBTXR3 in Head and Neck Cancer

NANOBIOTIX Recommends Phase 2 Dose for NBTXR3 in Pancreatic Cancer

NANOBIOTIX Updates Data from its Phase 1 Immunotherapy Study, Study 1100

NANOBIOTIX Announces the Appointment of Global Medical Experts to Scientific Advisory Board

Nanobiotix enters final agreement to restructure existing loan with EU's investment bank

Nanobiotix GAAP EPS of -€0.76, revenue of €1.33M beats by €0.11M

NANOBIOTIX Establishes Recommends Dose for Planned Registrational Study Evaluating NBTXR3 Plus Anti-PD-1 for Patients With Metastatic Head and Neck Cancer Resistant to Prior Immunotherapy

Nanobiotix agrees in principle to restructure debt obligations with EU's investment bank

Nanobiotix S.A. and LianBio Announce First Patient Enrolled in Asia in Phase 3 NANORAY-312 Trial Evaluating NBTXR3 for the Treatment of Head and Neck Cancer

French biotech Nanobiotix rebounds to post best ever 47% intraday gain

NANOBIOTIX Announces the Reporting of New Data at the 2022 Annual Meeting of the American Society for Clinical Oncology

Nanobiotix S.A. Announces the Reporting of New Data At the 2022 Annual Meeting of the American Society for Clinical Oncology

Nanobiotix S.A. to Report First Half, 2022 Results on Sep 28, 2022

Nanobiotix S.A. Announces New Data from an Open-Label Preclinical Study Evaluating the Combination of First-in-Class Radioenhancer, NBTXR3, with the Triple Blockade of PD-1, LAG-3, and TIGIT

Nanobiotix Announces Publication of New Clinical Case Study Highlighting First Patient Experience of NBTXR3 Treatment for Pancreatic Cancer

Nanobiotix S.A. Announces Publication of New Preclinical Immunotherapy Data Showcasing the Combination Potential of NBTXR3 With anti-PD-1 and anti-CTLA-4

Nanobiotix S.A. Announces First Patient Enrolled in NANORAY-312 Global Phase III Registrational Study of NBTXR3 in Head and Neck Cancer

Nanobiotix S.A. Announces Red Journal Publication of Preclinical Data Showing Radioenhancer NBTXR3 May 'Reprogram' the Tumor Microenvironment to Overcome Anti-PD-1 Resistance and Evoke Abscopal Effect

NANOBIOTIX Announces Initiation of New Clinical Study Evaluating NBTXR3 in Lung Cancer

NANOBIOTIX Reports New Data for Potential First-in-Class Radioenhancer NBTXR3 in Combination With Anti-PD-1 Showing Local or Distant Tumor Regression in 76.9% of Evaluable Patients Regardless of Prior Anti-PD-1 Exposure

Nanobiotix names Bart Van Rhijn as chief financial officer

Nanobiotix Announces Updated Results From Priority Pathways in Head and Neck Cancer and Immunotherapy for Potential First-in-class Radioenhancer NBTXR3 at 2021 Annual Meeting of the American Society for Clinical Oncology

Nanobiotix S.A. Announces New Data from its Oncology Pipeline to Be Present at the 2021 American Society of Clinical Oncology Annual Meeting

NANOBIOTIX and PharmaEngine, Inc. Mutually Agree to Conclude Collaboration

NANOBIOTIX Announces Positive New Preclinical Data Investigating First-In-Class Radioenhancer NBTXR3

Nanobiotix S.A. to Report Q2, 2021 Results on Sep 03, 2021

Nanobiotix Announces First Patient Injected with NBTXR3 in Esophageal Cancer

Nanobiotix Will Disrupt Oncological Radiotherapy

NANOBIOTIX Announces Positive First Results for Novel NBTXR3 in Rectal Cancer Study at ASCO-GI 2021

CEO報酬分析

CEO（最高経営責任者

在職期間

報酬

リーダーシップ・チーム

平均在職期間

平均年齢

取締役

平均在職期間

平均年齢

マネジメント基準チェック /14